IMS 2023 | MagnetisMM-3: correcting hypogammaglobulinemia & using Ig replacement therapy to reduce infections
In this video, Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, shares some insights into the challenges of treating viral infections in patients with relapsed/refractory (R/R) multiple myeloma following the administration of bispecific antibodies, namely elranatamab. Correcting hypogammaglobulinemia and using immunoglobulin (Ig) replacement therapy may reduce the risk and severity of infections in patients treated with these agents, and Prof. Leleu discusses findings from a post-hoc analysis of the MagnetisMM-3 trial (NCT04649359) which investigated the impact of these strategies on the risk of infection in this patient population. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
